A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Cytotoxic T-Lymphocyte-Associated Antigen-4
Clinical Cancer Research
Cancer immunotherapy relies on the ability of the immune system to target tumor-specific antigens to generate an immune response. This initial response requires both binding of the MHC/antigen peptide to T-cell receptor complex, along with a second costimulatory signal created by the binding of CD28 on the T cell, with B7 located on the antigen-presenting cell. Regulatory checkpoints, such as cytotoxic Tlymphocyte-associated antigen-4 (CTLA-4), serve to attenuate this signal, thereby preventingdoi:10.1158/1078-0432.ccr-10-2232 pmid:21467163 fatcat:2ddd7sxkvrejbmtjqjagxg6xdy